Prematüre Retinopatisinde Güncel Tedaviler

Öz

Son yıllarda yenidoğan yoğun bakım ünitelerinin yaygınlaşması ve yenidoğanbakımındaki gelişmelere paralel olarak tüm dünyada prematüre retinopatiinsidansında bir artış izlenmektedir. Bu durum taranması gereken prematür bebeksayısını ve tedavi edilmesi gereken göz sayısını arttırmaktadır. Bu derlemedekiamacımız prematüre retinopati tedavisindeki güncel yenilikleri değerlendirmektir.Tedavi alanında lazer ve kriyoterapiye alternatif veya birlikte uygulanabilen göz içineenjekte edilecek anti-anjiyojenik ilaçların kullanıma girmesi prematüriteretinopatisinin tedavisinde yeni ufuklar açabilecektir

Anahtar Kelimeler

• Prematürite retinopatisi,antianjiyojenik,tedavi

Current Treatments in Retinopathy of Prematurity

Öz

Increased worldwide incidences of retinopathy of prematurity have been noted dueto the recent devolepments in newborn care and increased availability of newbornintensive care units. Increased number of Newborn Intensive Care Units leads tosurvive of increased number of immature babies, therefore, there is an increasednumber of premature infants to be screened and eyes to be treated. The aim of thisreview is to evaluate the current improvements and treatment modalities inretinopathy of prematurity. Introduction of anti angiogenetic agents for intraocularinjection with or alternative to laser photocoagulation and criotherapy for treatmentmay broaden our view in the management of retinopathy of prematurity

Anahtar Kelimeler

• Retinopathy of prematurity,antiangiogenic,treatment

Kaynakça

1. 1. Terry TL. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens. Am J Ophthalmol 1942;25:203-4.
2. 2. Quiram PA, Capone A Jr. Current understanding and management of retinopathy of prematurity. Curr Opin Ophthalmol 2007;18:228-34.
3. 3. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Prognostic factors in the natural course of retinopathy of prematurity (Palmer EA, Schaffer DB, Plotsky DF: The Cryotherapy for Retinopathy of Prematurity Cooperative Group). Ophthalmology 1993;100:230-73.
4. 4. McLoone E, O’Keefe M, Lanigan B. Effect of diode laser retinal ablative therapy for threshold retinopathy of prematurity on the visual field: Results of Goldmann Perimetry at a mean age of 11 years. J Pediatr Ophthalmol Strabismus 2007;144:170-3.
5. 5. Quinn GE, Dobson V, Davitt BV, Hardy RJ, Tung B, Pedroza C et al. Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings to 3 years of age. Ophthalmology 2008;115:1058-64.
6. 6. Yıldız M, Özmen AT, Tör Ayvaz A, Yalçınbayır Ö, Kaderli B, Avcı R ve ark. Lazer tedavisi yapılan prematürite retinopatili olguların anatomik ve fonksiyonel sonuçları. Güncel Pediatri 2009;7:62-7.
7. 7. ICROP Committee: International classification of retinopathy of prematurity. Arch Ophthalmol 1984;102:1130-4.
8. 8. Good WV, Hardy RJ, Dobson V, Palmer EA, Phelps DL, Quintos M et al. Early Treatment for Retinopathy of Prematurity Cooperative Group. The incidence and course of retinopathy of prematurity: findings from the Early Treatment for Retinopathy of Prematurity Study. Pediatrics 2005;116:15-23.

9. 9. McNamara JA, Tasman W, Vander JF, Brown GC. Diode laser photocoagulation for retinopathy of prematurity: preliminary results. Arch Ophthalmol 1992;110:1714-6.
10. 10. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicentre trial of cryotherapy for retinopathy of prematurity: 3 1/2 year outcome structure and function. Arch Ophthalmol 1993;11:339-44.
11. 11. Noonan CP, Clark DI. Trends in the management of stage 3 retinopaty of prematurity. Br J Ophthalmol 1996;80:278-81.
12. 12. Ashton N. Retinal angiogenesis in the human embryo. Br Med Bull 1970;26:103-6.
13. 13. Chen J, Smith L. Retinopathy of Prematurity. Angiogenesis 2007;10:133-140.
14. 14. Smith LE, Wesolowski E, McLellan A, Kostyk SK, Amato DR, Sullivan R et al. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol Vis. Sci 1994;35:101-1.
15. 15. Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 1996;114:1219-28.
16. 16. Ostlund E, Bang P, Hagenas L, Fried G. Insulin-like growth factor I in fetal serum obtained by cordocentesis is correlated with intrauterine growth retardation. Hum Reprod 1997;12:840-4.
17. 17. Reece EA, Wiznitzer A, Le E, Homko CJ, Behrman H, Spencer EM. The relation between human fetal growth and fetal blood levels of insulin like growth factors I and II, their binding proteins, and receptors. Obstet Gynecol 1994;84:88-95.
18. 18. Young TL, Anthony DC, Pierce E, Foley E, Smith LE. Histopathology and vascular endothelial growth factor in untreated and diode laser treated retinopathy of prematurity. J AAPOS 1997;1:105-10.
19. 19. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92:10457-61.
20. 20. Smith LE, Shen W, Perruzzi C, Soker S, Kinose F, Xu X et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999;5:1390-5.
21. 21. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 1988;106:471-9.
22. 22. Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003;121:1684-94.
23. 23. Hardy RJ, Palmer EA, Schaffer DB, Phelps DL, Davis BR, Cooper CJ. Outcome-based management of retinopathy of prematurity. Multicenter Trial of Cryotherapy for Retinopathy of prematurity Cooperative Group. J AAPOS 1997;1:46-54.
24. 24. Hardy RJ, Palmer EA, Dobson V, Summers CG, Phelps DL et al. Tung B; Cryotherapy for Retinopathy of Prematurity Cooperative Group.Risk analysis of prethreshold retinopathy of prematurity. Arch Ophthalmol 2003;121:1697-701.
25. 25. Christiansen SP, Bradford JD. Cataract in infants treated with argon laser photocoagulation for threshold retinopathy of prematurity. Am J Ophthalmol 1995;119:175-80.
26. 26. Capone A Jr, Trese MT. Lens-sparing vitreous surgery for tractional stage 4A retinopathy of prematurity retinal detachments. Ophthalmology 2001;108:2068-70.
27. 27. Seaber JH, Machemer R, Eliott D, Buckley EG, deJuan E, Martin DF. Long-term visual results of children after initially successful vitrectomy for stage V retinopathy of prematurity. Ophthalmology 1995;102:199-204.
28. 28. Quinn GE, Dobson V, Barr CC, Davis BR, Palmer EA, Robertson J et al. Visual acuity of eyes after vitrectomy for retinopathy of prematurity: follow-up at 5 1/2 years. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 1996;103:595-600.
29. 29. Quinn GE, Dobson V, Barr CC, Davis BR, Flynn JT, Palmer EA et al. Visual acuity in infants after vitrectomy for severe retinopathy of prematurity. Ophthalmology 1991;98:5-13.
30. 30. Lashkari K, Hirose T, Yazdany J, McMeel JW, Kazlauskas A, Rahimi N. Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol 2000;156:1337-44.
31. 31. Sonmez K, Drenser KA, CaponeAJr, Trese MT. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology 2008;115:1065-70.
32. 32. Quiroz-Mercado H, Martinez-Castellanos M, HernandezRojas M, Salazar-Teran N, Chan P. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 2008;28:19-25.
33. 33. Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 2008;28:831-8.
34. 34. Dorta P, Kychenthal A. Treatment of type 1 retinopathy of prematur›ty w›th intravitreal bevacizumab. Retina 2010;30:24-31.
35. 35. Altinsoy HI, Mutlu FM, Güngör R, Sarici SU. Combination of Laser Photocoagulation and Intravitreal Bevacizumab in Aggressive Posterior Retinopathy of Prematurity. Ophthalmic Surg Lazers Imaging 2010 Mar 9:1-5.
36. 36. Mintz-Hittner HA, Best LM. Antivascular endothelial growth factor for retinopathy of prematurity. Curr Opin Pediatr 2009;21:182-7.